Ziosoft Seals Marketing Deal With Medicsight

A team of Johns Hopkins data researchers is studying the economic and safety implications associated with the devices used to perform colonoscopies as a disposable version inches closer to widespread availability.

Check-Cap Ltd. has initiated its U.S. pilot study of the C-Scan system for prevention of colorectal cancer through detection of precancerous polyps, following Institutional Review Board (IRB) approval and full Investigational Device Exemption (IDE) application approval by the U.S. Food and Drug Administration (FDA). The first patients have ingested C-Scan, a preparation-free capsule, at the New York University School of Medicine.

Check-Cap Ltd. announced the interim results for its post-CE approval study of the C-Scan system Version 3, an ingestible, capsule-based device for preparation-free colorectal cancer (CRC) screening. The company said data from the multicenter clinical investigation showed promising results for detecting patients with polyps in an un-prepped colon.

February 8, 2018 – The U.S. Food and Drug Administration (FDA) announced on February 7, 2018, that Pentax Medical’s ...

People with insurance policies that cover computed tomography (CT) colonography for colorectal cancer screening are almost 50 percent more likely to get screened than those whose policies don’t cover the procedure, according to a new study appearing online in the journal Radiology.